Cardiff Oncology, Inc. CRDF NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

36/100

1/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Cardiff Oncology, Inc. (CRDF) has a negative trailing P/E of -2.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 3.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -43.97%, forward earnings yield 32.26%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -2.3); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -43.97%).
Forward P/E 3.1 — analysts expect a return to profitability with estimated EPS of $0.55 for FY2030.
Trailing Earnings Yield -43.97% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 32.26% as earnings recover.

Overall SharesGrow Score: 34/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

36/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

FUTURE

55/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

0/100

→ Income

GROWTH

48/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — CRDF

Valuation Multiples

P/E (TTM)-2.3

Forward P/E3.1

PEG RatioN/A

Forward PEGN/A

P/B Ratio2.30

P/S Ratio179.85

EV/EBITDA-1.9

Per Share Data

EPS (TTM)$-0.69

Forward EPS (Est.)$0.55

Book Value / Share$0.68

Revenue / Share$0.01

FCF / Share$-0.57

Yields & Fair Value

Earnings Yield-43.97%

Forward Earnings Yield32.26%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-1.6	-0.07	3.21	166.32	38.25%
2017	-0.4	0.01	1.65	21.29	225.47%
2018	-0.5	0.01	0.73	19.60	327.13%
2019	-0.5	0.01	1.01	30.28	327.23%
2020	-19.5	0.32	2.93	1,026.07	-
2021	-8.3	0.26	1.67	653.40	0.01%
2022	-1.6	-0.07	0.57	158.13	0.68%
2023	-1.6	-0.36	0.95	135.50	-
2024	-4.6	-2.12	2.49	302.78	-
2025	-4.1	0.15	4.14	316.73	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-93.22	$381K	$-39.2M	-10289.8%
2017	$-51.71	$505K	$-24.91M	-4932.1%
2018	$-7.06	$378K	$-16.46M	-4354.8%
2019	$-2.70	$245K	$-16.15M	-6592.7%
2020	$-0.92	$365.99K	$-19.28M	-5267.8%
2021	$-0.71	$359K	$-27.74M	-7727.6%
2022	$-0.86	$386K	$-37.51M	-9716.6%
2023	$-0.93	$488K	$-41.44M	-8492%
2024	$-0.95	$683K	$-45.43M	-6651.7%
2025	$-0.69	$593K	$-45.88M	-7736.3%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.59	$-0.80 – $-0.44	$337.78K	$244.6K – $401.84K	6
2027	$-0.78	$-0.91 – $-0.65	$295K	$179.11K – $384.55K	5
2028	$-1.13	$-1.30 – $-0.74	$132K	$88K – $164.42K	5
2029	$-0.57	$-0.75 – $-0.32	$81.25M	$54.17M – $101.21M	1
2030	$0.55	$0.31 – $0.72	$231.43M	$154.28M – $288.27M	1